- Previous Close
22.25 - Open
23.00 - Bid 23.82 x 100
- Ask 24.18 x 100
- Day's Range
22.59 - 25.29 - 52 Week Range
2.01 - 25.77 - Volume
403,340 - Avg. Volume
143,452 - Market Cap (intraday)
661.021M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.74 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.33
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
www.lenz-tx.comRecent News: LENZ
View More
Performance Overview: LENZ
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LENZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LENZ
View MoreValuation Measures
Market Cap
661.02M
Enterprise Value
466.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-7.99
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-69.47M
Diluted EPS (ttm)
-2.74
Balance Sheet and Cash Flow
Total Cash (mrq)
196.11M
Total Debt/Equity (mrq)
0.88%
Levered Free Cash Flow (ttm)
--
Research Analysis: LENZ
View MoreCompany Insights: LENZ
LENZ does not have Company Insights